CERo Therapeutics Holdings, Inc.
CERO
$0.8899
-$0.0579-6.11%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.79M | 2.63M | 2.85M | 3.29M | 1.67M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.10M | 4.40M | 5.15M | 4.55M | 1.12M |
| Operating Income | -2.10M | -4.40M | -5.15M | -4.55M | -1.12M |
| Income Before Tax | 671.90K | -4.23M | -2.45M | -2.30M | -1.27M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 671.90K | -4.23M | -2.45M | -2.30M | -1.27M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 671.90K | -4.23M | -2.45M | -2.30M | -1.27M |
| EBIT | -2.10M | -4.40M | -5.15M | -4.55M | -1.12M |
| EBITDA | -2.00M | -4.29M | -5.03M | -4.44M | -1.01M |
| EPS Basic | -1.70 | -8.51 | -15.12 | -14.80 | -20.26 |
| Normalized Basic EPS | -1.34 | -5.32 | -11.17 | -13.07 | -12.74 |
| EPS Diluted | -1.70 | -8.51 | -15.12 | -14.80 | -20.26 |
| Normalized Diluted EPS | -1.34 | -5.32 | -11.17 | -13.07 | -12.74 |
| Average Basic Shares Outstanding | 1.24M | 496.80K | 162.00K | 116.70K | 62.50K |
| Average Diluted Shares Outstanding | 1.24M | 496.80K | 162.00K | 116.70K | 62.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |